MIAMI, FL--(Marketwire - March 31, 2010) -
Highlighted Links |
MacRepot Media |
Fourth Quarter and Full Year Results:
Fourth quarter 2009 revenue was up 85% to $5,367,906 compared to $2,900,245 for the same period a year ago. Operating Income was up 150% to $2,458,289 compared to $984,677 for the same period last year. Net Income was up 176% to $1,785,618 compared to $647,590 for the same quarter last year. Earnings per share for the fourth quarter of 2009 reached $0.10 compared to $0.05 for the same period in 2008.
Full year 2009 revenue reached $13,297,616 compared to $10,401,530 for the 2008 fiscal period, an increase of 28%. Full year 2009 operating income and net income reached $5,941,181 and $4,318,399 respectively compared to $4,651,796 and $3,350,299 respectively for fiscal 2008, an increase of 28% and 29%. Earnings per share for 2009 reached $0.27 compared to $0.24 for fiscal 2008.
Three months ended Twelve months ended 31-Dec 31-Dec ----------------------- ----------------------- 2009 2008 2009 2008 Sales revenue 5,367,906 2,900,245 13,297,616 10,401,530 Cost of sales (2,133,988) (520,256) (5,553,342) (3,939,610) ----------- ----------- ----------- ----------- Gross profit 3,233,918 1,848,884 7,744,274 6,461,920 ----------- ----------- ----------- ----------- Operating expenses Administrative expenses 238,585 522,565 947,251 1,117,729 R&D 178,833 278,103 378,497 444,404 Selling expenses 358,211 63,539 477,345 247,991 ----------- ----------- ----------- ----------- 775,629 864,207 1,803,093 1,810,124 ----------- ----------- ----------- ----------- Income from operations 2,458,289 984,677 5,941,181 4,651,796 Other income/(Expense) (65,267) (14,618) (129,227) (78,578) Income taxes (607,404) (336,768) (1,493,555) (1,222,919) ----------- ----------- ----------- ----------- Net income 1,785,618 647,590 4,318,399 3,350,299 =========== =========== =========== ===========
"We are pleased with our fourth quarter and full year results. The launch during the fourth quarter of our over the counter health product line and increased demand for our 5-HTP extract contributed to the increase in revenue and net income. We intend to increase distribution in China and abroad of our over the counter health product line in 2010," stated Min Zhao, Company CEO. "We are well positioned with a wide product portfolio to increase our performance in 2010," added Mr. Zhao.
About Green Planet
Green Planet Bioengineering Co., Ltd. ("Green Planet") (http://www.greenplanetbio.com) (OTCBB: GPLB), a subsidiary of ONE Bio, Corp. (OTCBB: ONBI), is a high-tech bioengineering enterprise that engages in research & development, production and sale of various extracts from tobacco leaves' residues destined for health supplements and organic agricultural products. Green Planet is headquartered in Miami, FL with its main operation located in Sanming and Fuzhou, China. Since founded in 2005, Green Planet offers a full range of high quality bio-ecological products which include raw chemical materials such as CoQ10 and Solanesol, organic fertilizers and pesticides and organic health nutrients and supplements. Company's unique position in the bioengineering industry comes from its R&D using patented cutting-edge methods to create abundant downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly products.
This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Green Planet Bioengineering, Co., Ltd. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and Green Planet Bioengineering, Co., Ltd. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Contact:
Investor Relations & Corporate Communications
888-676-4445
ir@greenplanetbio.com
Company Contact:
Jeanne Chan
Senior VP
Tel. +888-676-4445
jchan@onehcorp.com